OTCMKTS:AVCTF Avacta Group (AVCTF) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free AVCTF Stock Alerts $0.51 0.00 (0.00%) (As of 05/29/2024 ET) Add Compare Share Share Today's Range$0.51▼$0.5150-Day Range$0.51▼$0.6652-Week Range$0.51▼$2.17VolumeN/AAverage Volume3,195 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartShort InterestStock AnalysisChartShort Interest Get Avacta Group alerts: Email Address Ad WealthPressThe Tesla Indicator Is BullishIf you ever thought you’re too late to see significant returns from Tesla stock… Please read this short email. Because a world class trading expert just showed me an entirely new way to target hefty returns inside shares of Tesla. It’s all thanks to one unique trade setup that’s specific to this legendary stock. It’s called the Perfect Tesla Trade. And it couldn’t be more straightforward…>> Click here to join Lance now and he’ll teach you how to execute the Perfect Tesla Trade inside yo About Avacta Group Stock (OTCMKTS:AVCTF)Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.Read More AVCTF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVCTF Stock News HeadlinesMay 29 at 2:14 AM | americanbankingnews.comAvacta Group (OTCMKTS:AVCTF) Trading Down 14.5%May 18, 2024 | msn.comDown 63% in 2024, what’s going on with the Avacta (AVCT) share price?April 5, 2024 | finance.yahoo.comAvacta Group - AVA6000 Abstract Release by AACR and Full Presentation UpdateApril 4, 2024 | morningstar.comAvacta Group PLC AVCTFNovember 11, 2023 | morningstar.comAvacta Group PLC AVCTNovember 8, 2023 | finance.yahoo.comAvacta Group's (LON:AVCT) growing losses don't faze investors as the stock soars 11% this past weekOctober 5, 2023 | finance.yahoo.comAvacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSeptember 7, 2023 | finance.yahoo.comAvacta Group Plc (LON:AVCT) is largely controlled by institutional shareholders who own 53% of the companyJune 5, 2023 | lse.co.ukAvacta sees shares rise on new equity payment for South Korea ventureJune 1, 2023 | finance.yahoo.comAvacta Group's (LON:AVCT) investors will be pleased with their solid 218% return over the last five yearsMay 5, 2023 | finance.yahoo.comAvacta Group Plc's (LON:AVCT) Business Is Trailing The Industry But Its Shares Aren'tApril 7, 2023 | marketwatch.comAvacta Group's Shares Rise on US Site Openings for Cancer Study Patient EnrolmentApril 6, 2023 | lse.co.ukAvacta doses first patient in fifth cohort of AVA6000 phase 1 studyApril 6, 2023 | lse.co.ukAvacta opens first two clinical investigator sites in US for AVA6000April 5, 2023 | finance.yahoo.comAvacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation StudyApril 1, 2023 | finance.yahoo.comAvacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual MeetingMarch 31, 2023 | finanznachrichten.deAvacta Group plc: Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics DivisionMarch 31, 2023 | finance.yahoo.comAvacta Group Plc (LON:AVCT) is favoured by institutional owners who hold 55% of the companyJanuary 17, 2023 | benzinga.comAvacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical StudyDecember 1, 2022 | finance.yahoo.comInvestors in Avacta Group (LON:AVCT) have made a incredible return of 538% over the past three yearsSeptember 11, 2022 | fool.co.ukAvacta GroupSeptember 5, 2022 | finance.yahoo.comAvacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug AdministrationSeptember 1, 2022 | finance.yahoo.comAvacta Announces Phase I Clinical Study of AVA6000 to Advance to the Fourth CohortMay 3, 2022 | finance.yahoo.comEven though Avacta Group (LON:AVCT) has lost UK£39m market cap in last 7 days, shareholders are still up 304% over 3 yearsApril 13, 2022 | finance.yahoo.comAvacta Announces AffyXell Joint Venture Milestone and Increased Equity StakeSee More Headlines Receive AVCTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:AVCTF CUSIPN/A CIKN/A Webwww.avacta.com Phone44.1904.21.7070FaxN/AEmployees120Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. David Alastair Maclaughlin Smith (Age 58)CEO & Executive Director Comp: $555.35kMr. Tony Gardiner (Age 53)CFO, Company Secretary & Executive Director Comp: $341.46kDr. Christina Marie Coughlin B.S. (Age 54)M.D., Ph.D., Head of Research & Development, Interim Chief Medical Officer and Director Comp: $46.28kMs. Emma WrightGroup In-House CounselMr. Michael VinegradGroup Communications DirectorMr. R. Craig Slater FCA (Age 60)Chief Operating Officer of Diagnostics Comp: $86.3kDr. Matt JohnsonChief Scientific Officer of DiagnosticsDr. Fiona McLaughlin FSB (Age 54)Ph.D., Chief Scientific Officer of Therapeutics Division Mr. David WilsonChief Commercial Officer of DiagnosticsMs. Karen HarrisonChief Operating Officer of Therapeutics DivisionMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors AVCTF Stock Analysis - Frequently Asked Questions How have AVCTF shares performed in 2024? Avacta Group's stock was trading at $1.62 at the beginning of 2024. Since then, AVCTF stock has decreased by 68.5% and is now trading at $0.51. View the best growth stocks for 2024 here. How do I buy shares of Avacta Group? Shares of AVCTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:AVCTF) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWho are Nvidia’s New Silent Partners?Weiss RatingsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin Pro Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avacta Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.